Oppenheimer on Tandem Diabetes Care (TNDM): 'Strong Margins, Pharmacy Scaling Up'

August 7, 2026 6:13 AM

Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $22.00 price target on Tandem Diabetes Care (NASDAQ: TNDM).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found